Benzinga · Jul 30, 2026
GlucoTrack (GCTK) Stock Surges Over 70% After Hours: Why is it Moving?
GlucoTrack shares surged 70.25% after hours as investors reacted to its simplified single-injection strategy for LT-100 development.
NASDAQ · GCTK
Healthcare · Medical - Instruments & Supplies
$1.39
Down-$0.09 (-18.37%)
Updated Nov 3, 2026, 8:28 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GCTK
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
GCTK closed at $1.39 after 19 trading sessions, up 25.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $2.00 | $2.24 | $1.07 | $1.39 | 5.47M |
| Oct 28, 2026 | $2.00 | $2.50 | $1.80 | $2.05 | 28.29M |
| Oct 27, 2026 | $1.53 | $1.76 | $1.2901 | $1.71 | 4.72M |
| Oct 26, 2026 | $0.84 | $1.76 | $0.777 | $1.61 | 34.5M |
| Oct 23, 2026 | $1.18 | $1.2398 | $0.7458 | $0.8064 | 361.41K |
| Oct 22, 2026 | $1.218 | $1.3096 | $1.1208 | $1.1978 | 72.57K |
| Oct 21, 2026 | $1.3244 | $1.3492 | $1.2548 | $1.278 | 37.13K |
| Oct 20, 2026 | $1.354 | $1.355 | $1.18 | $1.3022 | 25.46K |
| Oct 19, 2026 | $0.7375 | $0.7375 | $0.682 | $0.6847 | 102.79K |
| Oct 16, 2026 | $0.8399 | $0.8399 | $0.7044 | $0.725 | 146.01K |
| Oct 15, 2026 | $0.88 | $0.88 | $0.76 | $0.8319 | 155.17K |
| Oct 14, 2026 | $1.10 | $1.10 | $0.8611 | $0.8873 | 361.4K |
| Oct 13, 2026 | $1.16 | $1.16 | $1.07 | $1.11 | 164.33K |
| Oct 12, 2026 | $1.09 | $1.1999 | $1.04 | $1.16 | 320.98K |
| Oct 9, 2026 | $1.12 | $1.12 | $1.00 | $1.03 | 236.59K |
| Oct 8, 2026 | $1.12 | $1.21 | $1.08 | $1.11 | 208.59K |
| Oct 7, 2026 | $1.12 | $1.16 | $1.10 | $1.15 | 105.23K |
| Oct 6, 2026 | $1.12 | $1.14 | $1.07 | $1.13 | 176.03K |
| Oct 5, 2026 | $1.16 | $1.2016 | $1.09 | $1.11 | 238.34K |
The latest Smart Investors Daily articles mentioning GCTK.
Company
Market Activity
Research & News
GCTK research
Company profile and research snapshot.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Jul 30, 2026
GlucoTrack shares surged 70.25% after hours as investors reacted to its simplified single-injection strategy for LT-100 development.
Benzinga · Jul 29, 2026
Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach
Benzinga · Jul 28, 2026
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12690787).pnhttps://x.com/PatentGrants/status/2082194682885587390
Benzinga · Jul 21, 2026
Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's regular session. The company's market cap stands at $36.8 million. Wellgistics Health (NASDAQ:WGRX) shares increased
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning GCTK.